CORT vs. TXMD

In the year-to-date period, CORT achieves a 57.48% return, which is significantly higher than TXMD's -51.11% return. Over the past 10 years, CORT has outperformed TXMD with an annualized return of 32.52%, while TXMD has yielded a comparatively lower -41.34% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Corcept Therapeutics Incorporated (CORT) and TherapeuticsMD, Inc. (TXMD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current CORT Sharpe Ratio is 1.17, which is higher than the TXMD Sharpe Ratio of -1.20. The chart below compares the historical Sharpe Ratios of CORT and TXMD, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither CORT nor TXMD has paid dividends to shareholders.

The maximum CORT drawdown since its inception was -94.28%, smaller than the maximum TXMD drawdown of -99.99%. Use the drawdown chart below to compare losses from any high point for CORT and TXMD. For additional features, visit the drawdowns tool.

Corcept Therapeutics Incorporated (CORT) and TherapeuticsMD, Inc. (TXMD) have volatilities of 11.97% and 12.07%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Corcept Therapeutics Incorporated and TherapeuticsMD, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.